Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy.

Abstract

Few studies have examined interindividual variability in the symptom experience of lung cancer patients. We aimed to identify the most prevalent, severe, and distressing symptoms, and risk factors associated with increased symptom burden. Lung cancer patients (n=145) reported occurrence, severity, and distress for 38 symptoms on the Memorial Symptom Assessment Scale 1week after chemotherapy. Using multidimensional subscales, risk factors for higher global distress, physical, and psychological symptoms were evaluated using simultaneous linear regression. Mean age was 64.0years and 56.6% were female. Mean Karnofsky Performance Status score was 79.1 (SD 14.6) and mean Self-Administered Comorbidity Questionnaire score was 7.3 (SD 3.9). The most distressing and prevalent symptom was fatigue. Problems with sexual interest/activity had the highest mean severity rating. Patients with lower functional status (p=0.001) and higher comorbidity (p=0.02) reported higher global distress. Similarly, lower functional status (p=0.003) and higher comorbidity (p=0.04) were associated with a higher physical symptom burden along with lower body mass index (p=0.02). Higher psychology symptom burden was associated with lower functional status (p=0.01), younger age (p=0.02), non-metastatic disease (p=0.03), higher number of prior treatments (p=0.04), and income (p=0.03). Fatigue was the most distressing and prevalent symptom among lung cancer patients receiving chemotherapy. Lower functional status was associated with a higher burden of global distress, physical, and psychological symptoms. Younger age and non-metastatic disease were additional risk factors for increased psychological symptoms. Together, these risk factors can help clinicians identify lung cancer patients at increased need for aggressive symptom management.